NCT07023029View on ClinicalTrials.gov

A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

September 12, 2025

Study Completion Date

September 15, 2025

Conditions
Healthy VolunteersSickle Cell DiseaseThalassemia
Interventions
DRUG

Etavopivat

Etavopivat will be administered orally.

DRUG

Moxifloxacin

Moxifloxacin will be administered orally.

DRUG

Placebo

Placebo matching Etavopivat will be administered orally.

Trial Locations (1)

21225

PAREXEL Intl - EPCU-Baltimore, Baltimore

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY